ERBB2 and breast cancer: Most recently, in the single-arm, multicenter PANACEA trial [66], pembrolizumab was studied in patients with advanced HER2+ breast cancer, who progressed while on the trastuzumab or T-DM1 therapy in this Phase Ib/II trial.